Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9H668

UPID:
STN1_HUMAN

ALTERNATIVE NAMES:
Oligonucleotide/oligosaccharide-binding fold-containing protein 1; Suppressor of cdc thirteen homolog

ALTERNATIVE UPACC:
Q9H668; D3DR99; Q5TCZ0

BACKGROUND:
CST complex subunit STN1, known alternatively as Suppressor of cdc thirteen homolog, is integral to the CST complex's function in DNA replication and repair. It binds single-stranded DNA, protecting telomeres and facilitating recovery from DNA damage. Its role extends beyond telomere maintenance to general replication start following replication-fork stalling, implicating new origin firing.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of CST complex subunit STN1 offers a promising pathway to developing treatments for diseases like Cerebroretinal microangiopathy with calcifications and cysts 2. The protein's involvement in DNA repair and replication stress response makes it a compelling candidate for drug discovery efforts aimed at mitigating the effects of genetic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.